这也正是亚投行自成立以来所关注的重点领域。据了解，亚投行近年来持续支持促进亚洲以及更广泛地 区的跨境基础设施互联互通项目。根据《中期发展战略（2021-2030）》，亚投行已将跨境互联互通与 区域合作列为四大业务优先方向之一，并明确到2030年跨境互联互通项目占比25%-30%。2024年，亚投 行的跨境互联互通项目占比已达33%，提前超额完成目标。 能源安全成重点 电网互联互通基础设施建设受重视 在当前全球推进互联互通的基础建设中，建设大规模区域电网等能源领域合作项目备受重视。 6月26日，在亚投行第十届理事会年会分论坛上，推动区域的互联互通成为重点讨论的话题之一。 与会人士普遍认为，提升区域的互联互通，能够有效发挥区域的资源互补优势，这对提升区域经济可持 续、高效发展，提升社会稳定性等具有重要意义。跨区域的电网等能源基础设施建设备受关注，如何能 够降低项目风险、高效推进成为多边机构与各国代表共同探讨的重要议题。 东盟电网正在如火如荼地推进中，这将有效地促进东盟地区电力设施的互联互通，也将成为带动东盟区 域经济发展的重要基础建设之一。印度尼西亚近期也宣布了其电力发展的计划。 为何区域电网备受关注？东盟能源中 ...

中新网上饶6月26日电 题：江西上饶女法官的"如我在诉"：卷宗间守公正 民生里见温情 2024年7月，王婧办理了一起客车买卖合同纠纷案件。案件中，外地公交公司因电池故障拒付200余万元 货款，原告要求被告按照合同支付全额货款，被告主张若支付货款则后续电池维修服务无法保障。 中新网记者 李韵涵 晚上八点，江西上饶市广信区人民法院旭日法庭的办公楼渐归寂静，但王婧办公室依旧亮着明灯。灯光 下，王婧埋首于数沓厚重的卷宗之间，指尖划过密密麻麻的法律条文，字里行间流淌着"如我在诉"的情 怀。 今年38岁的王婧，自2010年10月进入法院从事审判工作，如今是上饶市广信区人民法院旭日法庭庭长。 2019年以来，王婧累计办理民商事案件2138件，无一发回、无一错案、无一信访，审判质效领跑全省。 从"全国模范法官"到"全国先进工作者"，荣誉满身的她，办公桌日历本上却永远写满日程：开庭、调 解、走访企业…… 6月，王婧 在审理一起建设工程施工合同纠纷案件。江西高院 供图 旭日法庭是江西首家集"访、调、诉、执、破"于一体的专业化商事法庭。2022年5月，旭日法庭搬到企 业家门口——上饶经济技术开发区双创科技城，同时挂牌了上饶经济技术 ...

The AI revolution goes on. This is no doubt beneficial for the world's largest semiconductor foundry, which is the Taiwan Semiconductor Manufacturing Company (NYSE: TSM ). I have been holding shares of this company for severalWith a decade at a Big 4 audit firm specializing in the banking, mining, and energy sectors, I bring a strong foundation in finance and strategy. Currently, I serve as the Head of Finance for a leading owner and operator of retail real estate, where I oversee complex financial operatio ...

Core Viewpoint - Xiaomi is expanding its ecosystem with the launch of the AI glasses, positioning itself in the wearable technology market and aiming to enhance user interaction within its "human-vehicle-home" strategy [12][13][21] Product Launch - On June 26, Xiaomi held a "Human-Vehicle-Home Ecosystem Launch Conference," introducing several smart hardware products including the MIX Flip 2 foldable phone, Pad 7S Pro, and the highly anticipated YU 7 [1] - The AI glasses, weighing only 40g, are designed for comfort and come in three colors, with a price range of 1999 to 2999 yuan [7][9] Technical Features - The AI glasses feature a dual-chip Snapdragon AR1 processor, a 12MP ultra-wide-angle camera, and support for various AI tasks such as real-time image recognition and video live streaming [4][11] - They offer a battery life of 8.6 hours and can be charged in 45 minutes via a Type-C port [9] Market Positioning - The AI glasses are seen as a significant step for Xiaomi in the wearable device market, with over 50,000 pre-orders before the launch [12] - Xiaomi aims to capture the market for AI assistant-enabled wearables, leveraging its established supply chain and ecosystem [12][20] Strategic Importance - The introduction of AI glasses aligns with Xiaomi's broader strategy to create a seamless smart ecosystem that integrates various devices for enhanced user experience [13][17] - The glasses serve as a hardware platform for the "Super Xiao Ai" assistant, facilitating voice interaction and smart home control [16] Industry Impact - Xiaomi's entry into the AI glasses market is expected to lower consumer price expectations for smart eyewear, challenging the perception of AR glasses as high-priced tech gadgets [20] - The move is likely to stimulate interest in the smart glasses category, potentially revitalizing the supply chain and encouraging further innovation in the sector [20][21]

小米史上阵容最强大的发布会来了！ 发布会主打"人车家全生态"，雷军更是甩出了"全家桶"王炸，推出了众多新品，包含汽车、手机、平板以及智能穿戴设备等诸多领域，堪称一场科技盛宴。 雷军在发布会上表示，未来5年小米研发投入预计2000亿。 巨额科研投入，正持续转化为小米的市场竞争力。从影像技术突破到玄戒芯片，从快充迭代到人车家生态构建，研发成果不断夯实小米产品力。 关于小米的成功经验，雷军表示，面对困难时，企业必须坚定信心，相信中国的科技创新能力和市场潜力。 YU7硬刚Model Y 今晚最受关注的，还是小米首款SUV——YU7！ 此次，小米YU7带来高达9款的配色外观，高饱和度的跑车色系、青春靓丽的时尚色系、逼格满满的豪华色系，还有一款经典的珍珠白。 小米YU7延续了SU7的设计语言，全系采用800伏碳化硅高压平台，支持5.2C超充技术，充电15分钟即可补充620公里续航。 这一补能效率直接碾压特斯拉超充网络，彻底化解里程焦虑。 底盘系统上，Pro与Max版配备连续阻尼可变减振器+双腔空悬，在运动与舒适间无缝切换；Max版更搭载Brembo四活塞卡钳，将赛道基因注入SUV车身。 座舱交互上，也迎来了颠覆性创新—— ...

Key Takeaways GE Vernova should gain from floating wind growth, supported by its offshore expertise. GEV's Haliade-X turbines operate in major North Sea fixed-bottom wind projects. GEV proposed a floating Haliade-X in 2021 and serviced a major European floating wind farm in 2024.As the world undergoes a revolutionary energy transition process, a significant expansion in floating offshore wind farms is being witnessed recently. The installation of wind turbines further ashore will enable these farms to cap ...

Core Insights - Everest Medicines is hosting a virtual event on June 30, 2025, to discuss the latest results from the Phase 1b/2a clinical trial of EVER001, a next-generation covalent reversible BTK inhibitor for treating Primary Membranous Nephropathy (pMN) [1][2] Group 1: Clinical Trial and Treatment Landscape - The event will provide an overview of pMN and the current treatment landscape in the U.S. and China, along with the latest data from the EVER001 trial as of March 21, 2025 [2] - Everest recently reported positive preliminary results from the EVER001 study at the European Renal Association, with patient follow-up data as of December 14, 2024 [3] - There are approximately 2 million patients with pMN in China and nearly 220,000 patients in the U.S., Europe, and Japan, with no approved drugs for this condition globally [3][6] Group 2: About EVER001 - EVER001, previously known as XNW1011, is a next-generation covalent reversible BTK inhibitor being developed for renal diseases [5] - BTK is crucial for B-cell receptor signaling pathways that regulate B lymphocyte functions, and targeting BTK has shown effectiveness in treating B-cell lymphomas and autoimmune diseases [5] Group 3: About Primary Membranous Nephropathy (pMN) - pMN is a common pathological type of nephrotic syndrome in adults, with its prevalence in China increasing, ranking second only to IgA nephropathy [6] - The current treatment goals for pMN include improving remission rates, reducing relapse rates, and minimizing chronic toxicity risks from existing treatments [6] Group 4: About Everest Medicines - Everest Medicines focuses on discovering, developing, manufacturing, and commercializing transformative pharmaceutical products and vaccines to address unmet medical needs [7][8] - The management team has extensive expertise from leading global and local pharmaceutical companies, with a portfolio of potentially first-in-class or best-in-class molecules in renal diseases, infectious diseases, and autoimmune disorders [8]

Key Information - Rathbones Group Plc disclosed a position in Tritax Big Box REIT Plc, holding 28,233,149 relevant securities, representing 1.13% of the total [1][3] - The position was disclosed as of June 25, 2025, with the formal disclosure made on June 26, 2025 [1][14] - The disclosure includes both interests and short positions, with no short positions reported [3] Positions - Rathbones Group Plc holds 28,233,149 ordinary shares of Tritax Big Box REIT Plc, which constitutes 1.13% of the relevant securities [3] Dealings - Rathbones Group Plc sold a total of 98,965 ordinary shares of Tritax Big Box REIT Plc at prices of 146.5p and 146.2643p per unit [7] - Additionally, there was a transfer out of 4,195 ordinary shares, although no price per unit was specified [11] Other Information - There are no indemnity or option arrangements related to the relevant securities disclosed by Rathbones Group Plc [12] - No agreements or understandings regarding voting rights or future acquisition or disposal of relevant securities were reported [13]

Investors in Air Products and Chemicals, Inc. (APD) need to pay close attention to the stock based on moves in the options market lately. That is because the July 18, 2025 $165.00 Put had some of the highest implied volatility of all equity options today.What is Implied Volatility?Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the othe ...

Key Takeaways WST is seeing strong growth from GLP-1-related high-value components and auto-injector demand. WST's Annex 1 projects are driving a favorable mix shift toward higher-margin pharma offerings. Margin pressure stems from WST's lower-margin product growth, pricing headwinds and $20-$25M in new tariffs.West Pharmaceutical Services, Inc. (WST) is well-positioned for growth, backed by the robust GLP-1 related demand and its expansion plans. However, pricing headwinds and tariff risks are concerning ...